AEON Biopharma Q3 cash $16.2M; Phase 2 episodic migraine misses primary endpoint

AEON Biopharma, Inc.

2023-Q3 EPS reported $1.19

Cash, equivalents and investments $16.2M as of Sep 30, 2023; expects to fund operations only into mid-December 2023.
Phase 2 episodic migraine trial missed primary endpoint: mean MMD reduction 4.8 (150U) and 5.0 (195U) vs 4.2 placebo, not statistically significant.
Secondary endpoints achieved statistical significance; company plans to advance to Phase 3 and request end-of-phase 2 meeting with FDA in 1H 2024.
Chronic migraine Phase 2 enrollment on track to complete Q4 2023, topline data expected 2H 2024.
Completed business combination and post-merger funding of ~$50M from new and existing investors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AEON Biopharma, Inc. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

AEON Biopharma, Inc. (the "Company") announced financial results for the fiscal quarter ended September 30, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

AEON Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-018705

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.